Aditxt signs second amendment to arrangement agreement with Appili Therapeutics
60% off Profit Pro - Limited to first 500 users
3.15MUSD
Type
Common Stock
Exchange
PINK
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
CA03783R1073
CUSIP
-
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
March
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
-
Book Value
-0.09
Dividend Share
-
Dividend Yield
-
Earnings Share
-0.02
Wall Street Target Price
0.15
EPS Estimate Current Year
0
EPS Estimate Next Year
0
EPS Estimate Current Quarter
0
EPS Estimate Next Quarter
0
Most Recent Quarter
-
Revenue TTM
827,407
Gross Profit TTM
1,390,684
EBITDA
-8,590,420
Profit Margin
0.00%
Return On Assets TTM
-244.22%
Return On Equity TTM
-938.72%
Revenue Per Share TTM
0.007
Qtly Revenue Growth YOY
-96.50%
Diluted Eps TTM
-0.02
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
1
Price Sales TTM
8.8014
Price Book MRQ
1.4792
Enterprise Value Revenue
28
Enterprise Value EBITDA
-2
467.80
0.74%91.85
0.72%97.79
0.25%616.55
0.07%525.60
0.00%173.75
0.00%174.00
0.00%118.00
-2.24%750.00
-0.68%253.07
-0.21%Cart
Aditxt signs second amendment to arrangement agreement with Appili Therapeutics
Aditxt signs agreement to acquire Appili Therapeutics